1/1
Early Itch Response with Abrocitinib is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE 3 COMPARE Trial
media
posted on 2022-12-04, 22:31 authored by Adis Journals on behalf of:, Sonja Ständer, Shawn G. Kwatra, Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen, Gil Yosipovitch, Fan Zhang, Michael C. Cameron, Ricardo Rojo Cella, Hernan Valdez, Marco DiBonaventura, Claire FeeneyArticle full text
The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2022
